Atossa Therapeutics
ATOS
12 hedge funds and large institutions have $175K invested in Atossa Therapeutics in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
9% more funds holding
Funds holding: 11 → 12 (+1)
1.32% less ownership
Funds ownership: 3.41% → 2.08% (-1.3%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
64% less capital inflows, than outflows
Capital inflows: $57.7K | Capital outflows: $162K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.8K |
| 2 |
Kingsview Wealth Management
Grants Pass,
Oregon
|
+$22.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.55K |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
+$1.02K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$509 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$131K |
| 2 |
Two Sigma Securities
New York
|
-$27K |
| 3 |
Panagora Asset Management
Boston,
Massachusetts
|
-$2.11K |
| 4 |
MFW
Mosaic Family Wealth
St. Louis,
Missouri
|
-$1K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$509 |
ATOS Hedge Fund Activity: Q4 2017 in Review
12 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2017, worth a combined $175K — down 63% from $478K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ATOS positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $30.8K. The largest seller was Renaissance Technologies, cutting an estimated $131K.
- 12 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2017, up from 11 in Q3 2017.
- Funds reported $175K of Atossa Therapeutics stock for Q4 2017, down 63% quarter-over-quarter.
- 4 funds opened new Atossa Therapeutics positions in Q4 2017 and 3 closed out, a net change of +1 holder.
- The largest Atossa Therapeutics buyer in Q4 2017 was Vanguard Group, an estimated $30.8K added.
- The largest Atossa Therapeutics seller in Q4 2017 was Renaissance Technologies, an estimated $131K sold.
Based on aggregated 13F filings for Q4 2017.